Catalyst Pharmaceuticals Inc
CPRXHealthcare|Biotechnology|USA
$31.48
+0.00 (+0.00%)
DCF (FCF)
$21.18
Tangible Book
$7.29
Graham Number
$18.16
Earnings Power
$15.91
Upcoming Data Readouts (5)
Sep 2026
Est. completion
P2Acute Myeloid Leukemia
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
NCT05796570n=37
Nov 2026
Est. completion
NADSD
Breaking Silence Through Story: A Narrative Medicine Intervention for Parents of Children With Urogenital Conditions
NCT06989593n=20
Feb 2028
Est. completion
P1PROC
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT07470853n=265
Dec 2028
Est. completion
Feb 2032
Est. completion
Duchenne Muscular Dystrophy
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
NCT06564974n=250
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
May 2026
P2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
NCT05556824